1154 related articles for article (PubMed ID: 20141835)
1. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
Heidorn SJ; Milagre C; Whittaker S; Nourry A; Niculescu-Duvas I; Dhomen N; Hussain J; Reis-Filho JS; Springer CJ; Pritchard C; Marais R
Cell; 2010 Jan; 140(2):209-21. PubMed ID: 20141835
[TBL] [Abstract][Full Text] [Related]
2. Raf inhibitors target ras spatiotemporal dynamics.
Cho KJ; Kasai RS; Park JH; Chigurupati S; Heidorn SJ; van der Hoeven D; Plowman SJ; Kusumi A; Marais R; Hancock JF
Curr Biol; 2012 Jun; 22(11):945-55. PubMed ID: 22560614
[TBL] [Abstract][Full Text] [Related]
3. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
Rebocho AP; Marais R
Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515
[TBL] [Abstract][Full Text] [Related]
4. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
Wang P; Laster K; Jia X; Dong Z; Liu K
Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
[TBL] [Abstract][Full Text] [Related]
5. Computer-aided design and synthesis of 3-carbonyl-5-phenyl-1
Kim J; Choi B; Im D; Jung H; Moon H; Aman W; Hah JM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1314-1320. PubMed ID: 31307243
[TBL] [Abstract][Full Text] [Related]
6. The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.
Riaud M; Maxwell J; Soria-Bretones I; Dankner M; Li M; Rose AAN
Nat Rev Cancer; 2024 Feb; 24(2):105-122. PubMed ID: 38195917
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
[TBL] [Abstract][Full Text] [Related]
8. (G12D) NRAS and kinase-dead BRAF cooperate to drive naevogenesis and melanomagenesis.
Pedersen M; Viros A; Cook M; Marais R
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1162-6. PubMed ID: 25043451
[No Abstract] [Full Text] [Related]
9. Development of a High-throughput NanoBRET Screening Platform to Identify Modulators of the RAS/RAF Interaction.
Durrant DE; Smith EA; Goncharova EI; Sharma N; Alexander PA; Stephen AG; Henrich CJ; Morrison DK
Mol Cancer Ther; 2021 Sep; 20(9):1743-1754. PubMed ID: 34158349
[TBL] [Abstract][Full Text] [Related]
10. Regulation of RAF family kinases: new insights from recent structural and biochemical studies.
Spencer-Smith R; Morrison DK
Biochem Soc Trans; 2024 May; ():. PubMed ID: 38695730
[TBL] [Abstract][Full Text] [Related]
11. RASopathy mutations provide functional insight into the BRAF cysteine-rich domain and reveal the importance of autoinhibition in BRAF regulation.
Spencer-Smith R; Terrell EM; Insinna C; Agamasu C; Wagner ME; Ritt DA; Stauffer J; Stephen AG; Morrison DK
Mol Cell; 2022 Nov; 82(22):4262-4276.e5. PubMed ID: 36347258
[TBL] [Abstract][Full Text] [Related]
12. Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation.
Trebino TE; Markusic B; Nan H; Banerjee S; Wang Z
Elife; 2023 Dec; 12():. PubMed ID: 38150000
[TBL] [Abstract][Full Text] [Related]
13. Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation.
Trebino T; Markusic B; Nan H; Banerjee S; Wang Z
bioRxiv; 2023 Sep; ():. PubMed ID: 37163002
[TBL] [Abstract][Full Text] [Related]
14. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
15. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
Dahlman KB; Xia J; Hutchinson K; Ng C; Hucks D; Jia P; Atefi M; Su Z; Branch S; Lyle PL; Hicks DJ; Bozon V; Glaspy JA; Rosen N; Solit DB; Netterville JL; Vnencak-Jones CL; Sosman JA; Ribas A; Zhao Z; Pao W
Cancer Discov; 2012 Sep; 2(9):791-7. PubMed ID: 22798288
[TBL] [Abstract][Full Text] [Related]
16. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB; Hauschild A; Robert C; Haanen JB; Ascierto P; Larkin J; Dummer R; Garbe C; Testori A; Maio M; Hogg D; Lorigan P; Lebbe C; Jouary T; Schadendorf D; Ribas A; O'Day SJ; Sosman JA; Kirkwood JM; Eggermont AM; Dreno B; Nolop K; Li J; Nelson B; Hou J; Lee RJ; Flaherty KT; McArthur GA;
N Engl J Med; 2011 Jun; 364(26):2507-16. PubMed ID: 21639808
[TBL] [Abstract][Full Text] [Related]
17. Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.
Sen B; Peng S; Tang X; Erickson HS; Galindo H; Mazumdar T; Stewart DJ; Wistuba I; Johnson FM
Sci Transl Med; 2012 May; 4(136):136ra70. PubMed ID: 22649091
[TBL] [Abstract][Full Text] [Related]
18. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z; Yaeger R; Rodrik-Outmezguine VS; Tao A; Torres NM; Chang MT; Drosten M; Zhao H; Cecchi F; Hembrough T; Michels J; Baumert H; Miles L; Campbell NM; de Stanchina E; Solit DB; Barbacid M; Taylor BS; Rosen N
Nature; 2017 Aug; 548(7666):234-238. PubMed ID: 28783719
[TBL] [Abstract][Full Text] [Related]
19. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
20. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
Yao Z; Torres NM; Tao A; Gao Y; Luo L; Li Q; de Stanchina E; Abdel-Wahab O; Solit DB; Poulikakos PI; Rosen N
Cancer Cell; 2015 Sep; 28(3):370-83. PubMed ID: 26343582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
